Benefits of GLP-1 receptor agonists therapy for patients with cardiovascular disease
Authors:
Martin Haluzík 1; Michal Vrablík 2
Authors‘ workplace:
Centrum diabetologie IKEM, Praha
1; Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
2
Published in:
AtheroRev 2022; 7(2): 85-90
Category:
Reviews
Overview
Cardiovascular complications are main cause of increased mortality in patients with type 2 diabetes. Decrease of overall cardiovascular risk and subsequently cardiovascular morbidity and mortality in type 2 diabetes patients is therefore an important treatment aim. To this end, intensive intervention of classical risk factors such as dyslipidemia, arterial hypertension, smoking along with lifestyle intervention is necessary. Satisfactory glucose control optimally with the use of antidiabetic medication with positive effect on cardiovascular complication is of high importance as well. The aim of this paper is to summarize the use GLP-1 receptor agonists in patients with type 2 diabetes within the context of other treatment option focusing on the their cardiovascular effects and their influence on cardiovascular complications.
Keywords:
type 2 diabetes mellitus – cardiovascular complications – GLP-1 receptor agonists – cardioprotectivity
Sources
1. O‘Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314(7085): 955–959. Dostupné z DOI: <http://doi: 10.1136/bmj.314.7085.955>.
2. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013; 27(2): 163–177. Dostupné z DOI: <http://doi: 10.1016/j.beem.2013.02.005>.
3. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207–223. Dostupné z DOI: <http://doi: 10.1210/rp.59.1.207>.
4. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–234. Dostupné z DOI: <http://doi: 10.1056/NEJM199807233390404>.
5. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017; 389(10085):2239–2251. Dostupné z DOI: <http://doi: 10.1016/S0140–6736(17)30058–2>.
6. Johnston SS, Conner C, Aagren M et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34(5): 1164–1170. Dostupné z DOI: <http://doi: 10.2337/dc10–1915>.
7. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36(11–12): 852–858. Dostupné z DOI: <http://doi: 10.1055/s-2004–826175>.
8. Davies MJ, D‘Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669–2701. Dostupné z DOI: <http://doi: 10.2337/dci18–0033>.
9. Kuritzky L, Umpierrez G, Ekoe JM et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med 2014; 126(6): 60–72. Dostupné z DOI: <http://doi: 10.3810/pgm.2014.10.2821>.
10. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31(11): 2472–2488. Dostupné z DOI: <http://doi: 10.1016/j.clinthera.2009.11.034>.
11. Htike ZZ, Zaccardi F, Papamargaritis D et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19(4): 524–536. Dostupné z DOI: <http://doi: 10.1111/dom.12849>.
12. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012; 14(8): 762–767. Dostupné z DOI:<http://doi: 10.1111/j.1463–1326.2012.01603.x>.
13. Madsbad S, Kielgast U, Asmar M et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13(5): 394–407. Dostupné z DOI: <http://doi: 10.1111/j.1463–1326.2011.01357.x>.
14. Capehorn MS, Catarig AM, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 2020; 46(2): 100–109. Dostupné z DOI: <http://doi:10.1016/j.diabet.2019.101117>.
15. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384(9951): 1349–1357. Dostupné z DOI: <http://doi: 10.1016/S0140–6736(14)60976–4>.
16. Pratley RE, Aroda VR, Lingvay I et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018; 6(4): 275–286. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(18)30024-X>.
17. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394(10192): 39–50. Dostupné z DOI: <http://doi: 10.1016/S0140–6736(19)31271–1>.
18. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61–69. Dostupné z DOI: <http://doi:10.1016/j.ahj.2020.07.008>.
19. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356:2457–2471. Dostupné z DOI: <http://doi: 10.1056/NEJMoa072761>.
20. Guidance for Industry Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Dostupné z WWW: <http://www.fda.gov/cder/guidance/index.htm>.
21. Kristensen SL, Rørth R, Jhund PS et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology 2019; 7(10): 776–785. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(19)30249–9>.
22. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The Lancet Diabetes & Endocrinology 2014; 2(4): 289–297. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(13)70214–6>.
23. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4):311–322. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1603827>.
24. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19):1834–1844. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1607141>.
25. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841–851. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1901118>.
26. Jorsal A, Kistorp C, Holmager P et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double--blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017; 19(1):69–77. Dostupné z DOI: <http://doi: 10.1002/ejhf.657>.
27. Meier JJ, Rosenstock J, Hincelin-Mery A et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015; 38(7): 1263–1273. Dostupné z DOI: <http://doi: 10.2337/dc14–1984>.
28. Barale C, Buracco S, Cavalot F et al. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb Haemost 2017; 117(6): 1115–1128. Dostupné z DOI: <http://doi: 10.1160/TH16–07–0586>.
29. Li Q, Tuo X, Li B et al. Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats. Life Sciences. 2020; 250: 117531. Dostupné z DOI: <http://doi:10.1016/j.lfs.2020.117531>.
30. Chang W, Zhu F, Zheng H et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDLinduced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis. Mol Immunol 2019; 116: 73–79. Dostupné z DOI: <http://doi: 10.1016/j.molimm.2019.09.021>.
31. Bruen R, Curley S, Kajani S et al. Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E-deficient mice via regulation of immune cell phenotypes and proinflammatory mediators. J Pharmacol Exp Ther 2019; 370(3): 447–458. Dostupné z DOI: <http://doi: 10.1124/jpet.119.258343>.
32. Yang X, Feng P, Zhang X et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 2019; 158: 107748. Dostupné z DOI: <http://doi: 10.1016/j.neuropharm.2019.107748>.
33. Jojima T, Uchida K, Akimoto K et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis 2017; 261:44–51. Dostupné z DOI: <http://doi: 10.1016/j.atherosclerosis.2017.04.001>.
34. Rakipovski G, Rolin B, Nohr J et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci 2018; 3(6): 844–857. Dostupné z DOI: <http://doi: 10.1016/j.jacbts.2018.09.004>.
35. Buse JB, Bain SC, Mann JFE et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care 2020; 43(7):1546–1552. Dostupné z DOI: <http://doi: 10.2337/dc19–2251>.
36. Colhoun HM, Hasnour C, Riddle MC et al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND (abstract 924-P). Diabetes 2020; 69(Suppl 1). Dostupné z WWW: <http://www.diabetesjournals.org>.
37. Hermansen K, Bækdal TA, Düring M et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab 2013; 15(11): 1040–1048. Dostupnéz DOI: <http://doi: 10.1111/dom.12133>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2022 Issue 2
Most read in this issue
- Benefits of GLP-1 receptor agonists therapy for patients with cardiovascular disease
- Lysosomal acid lipase deficiency – differential diagnosis and treatment options in 2022
- How are we doing in achieving target LDL-cholesterol levels in the high-risk population in Slovakia: retrospective study
- Lifelong exposure and trajectories of the risk factors – a new direction in prediction of CVD risk